Business Wire

BARTEK-INGREDIENTS

25.1.2023 21:05:42 CET | Business Wire | Press release

Share
Bartek Hosts Canadian Government Dignitaries at Facility Groundbreaking

Bartek Ingredients advances its plans to strengthen its position as the world’s largest producer of malic and food-grade fumaric acid with the groundbreaking of its state-of-the-art, $175 million malic and fumaric acid production facility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005653/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Left to right: Tim Larson (Bartek), Minister Neil Lumsden, MP Chad Collins, Minister Lisa Thompson, Hamid Goli (Bartek), Jose Kafie (Bartek), John Burrows (Bartek), Jim Vincent (Bartek), Steven Chambers (Bartek), Minister Vic Fedeli. (Photo: Business Wire)

The company held a groundbreaking ceremony on Jan. 12 with Canadian government officials and local community leaders to celebrate the official commencement of the construction project.

“We are thrilled to be breaking ground on our new facility which will set a new global benchmark for safety, efficiency, and environmental performance,” Bartek President and CEO John Burrows said. “We are pleased to be investing in the community of Stoney Creek and proud to play an integral part in supporting local industries and the local economy. We are thankful for our partnerships with the provincial and federal government and Environment Hamilton and their support and guidance throughout the process.”

Among those in attendance at the groundbreaking were Neil Lumsden, Minister of Tourism, Culture and Sport and Member of Provincial Parliament for Hamilton East, Victor Fedeli, Minister of Economic Development and Trade, Lisa Thompson, Minister of Agriculture, Food and Rural Affairs, and Chad Collins, Member of Federal Parliament for Hamilton East-Stoney Creek.

“Congratulations to everyone at Bartek Ingredients on this exciting milestone,” Minister Fedeli said. “Bartek’s $175 million investment will ensure that the company can continue to expand and create more good-paying jobs in Hamilton and the surrounding region. Together, we’re building a stronger Ontario with opportunities for all people.”

The facility will double Bartek’s production capacity and propel new product development and other innovation efforts. It is also being built with sustainability in mind and is expected to be the most environmentally sustainable facility in the industry – projected to reduce per unit greenhouse gas emissions by more than 80 percent.

“Ontario has a clean energy advantage and is a sustainable and predictable place to do business,” Minister Piccini said. “As a result, we’re attracting the jobs of tomorrow. My Ministry was proud to work closely with Bartek through the permitting and approvals process to help secure this significant investment to Ontario.”

Minister Thompson added: “Bartek’s new state-of-the-art facility will be a shining example of Ontario’s robust agri-food manufacturing and processing sector. This major investment will create good-paying jobs in the local community and further strengthen Ontario’s value-added food supply chain.”

Through this project, Bartek will inject $100 million into the local Stoney Creek economy. The facility is expected to be fully operational at the beginning of 2024.

“Hamilton’s Bartek facility will soon become one of the world’s largest malic and food-grade acid production plants,” Minister Lumsden said. “Our government is excited to see local manufacturers, such as Bartek, invest in Ontario to grow and create more good-paying jobs right here in Hamilton!”

For more information, please visit bartek.ca or contact Bartek at info@bartek.ca.

About Bartek Ingredients

For over 50 years, Bartek Ingredients Inc. has been a leading global manufacturer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. With new ownership in 2019 and significant investments, Bartek’s presence in the food and beverage space continues to be bolstered by highly innovative products and services that utilize deep product expertise and application knowledge to offer solutions to industry needs. For more information about Bartek, visit bartek.ca/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005653/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye